Security key
640979100
Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA)
CUSIP: 640979100
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 186,788,806
- Total 13F shares
- 62,936,207
- Share change
- +12,139,290
- Total reported value
- $112,659,183
- Put/Call ratio
- 8.9%
- Price per share
- $1.79
- Number of holders
- 100
- Value change
- +$21,662,425
- Number of buys
- 55
- Number of sells
- 33
Report period
Q4 2025
Institutions
100
Top holders
10
NMRA full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Neumora Therapeutics, Inc. SEC filings
Neumora Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 640979100
Recent filing periods:
Top shareholders of NMRA - Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| AMGEN INC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
35,368,653
|
$423,716,463 | — | 19 Sep 2023 | |
| FMR LLC |
3/4/5
13D/G
13F
|
Other* · Company |
2.2%
from 13D/G
|
5,624,353
|
$67,379,749 | — | 19 Sep 2023 | |
| Kristina Burow |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
33,975,555
mixed-class rows
|
$66,466,963 | +$4,999,977 | 27 Oct 2025 | |
| ARCH Venture Partners X, LLC |
3/4/5
|
10%+ Owner |
18%
|
33,847,838
|
$66,380,119 | +$4,999,977 | 27 Oct 2025 | |
| ARCH Venture Partners XII, LLC |
3/4/5
|
10%+ Owner |
18%
|
33,847,838
|
$66,380,119 | +$4,999,977 | 27 Oct 2025 | |
| SOFTBANK GROUP CORP. |
13F
|
Company |
3.5%
|
6,541,190
|
$11,904,966 | — | 30 Sep 2025 | |
| MIC Capital Management UK LLP |
13F
|
Company |
2.4%
|
4,460,700
|
$8,118,474 | — | 30 Sep 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
2.3%
|
4,358,283
|
$7,932,075 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.2%
|
4,049,167
|
$7,369,484 | — | 30 Sep 2025 | |
| Gosebruch Henry O |
3/4/5
|
President & CEO, Director |
—
mixed-class rows
|
749,793
mixed-class rows
|
$7,065,720 | — | 14 Feb 2024 | |
| Paul L. Berns |
13D/G
|
— |
5.1%
|
8,226,272
|
$6,334,229 | $0 | 31 Dec 2024 | |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST |
13F
|
Company |
1.8%
|
3,309,123
|
$6,022,604 | — | 30 Sep 2025 | |
| ICONIQ Capital, LLC |
13F
|
Company |
1.4%
|
2,559,090
|
$4,657,544 | — | 30 Sep 2025 | |
| Carol Y. Suh |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
544,674
mixed-class rows
|
$4,488,595 | — | 14 Feb 2024 | |
| Lunate Capital Ltd |
13F
|
Company |
1.1%
|
2,124,143
|
$3,865,940 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.1%
|
2,008,248
|
$3,655,011 | — | 30 Sep 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
1%
|
1,938,100
|
$3,528,000 | — | 30 Sep 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
0.99%
|
1,849,445
|
$3,365,990 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.97%
|
1,815,930
|
$3,304,992 | — | 30 Sep 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.75%
|
1,400,000
|
$2,548,000 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.62%
|
1,163,976
|
$2,118,436 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.52%
|
977,000
|
$1,778,140 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.52%
|
968,928
|
$1,764,252 | — | 30 Sep 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.44%
|
830,818
|
$1,512,089 | — | 30 Sep 2025 | |
| AlphaCore Capital LLC |
13F
|
Company |
0.34%
|
638,784
|
$1,162,587 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.27%
|
512,939
|
$933,549 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.23%
|
424,244
|
$772,124 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.21%
|
388,919
|
$707,833 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.2%
|
377,374
|
$686,820 | — | 30 Sep 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.17%
|
314,119
|
$571,697 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.16%
|
299,814
|
$545,661 | — | 30 Sep 2025 | |
| Cerity Partners LLC |
13F
|
Company |
0.15%
|
288,515
|
$525,097 | — | 30 Sep 2025 | |
| Robert A. Lenz |
3/4/5
|
Head of R&D |
—
mixed-class rows
|
409,092
mixed-class rows
|
$516,616 | — | 18 Feb 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.15%
|
274,767
|
$500,075 | — | 30 Sep 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.15%
|
272,482
|
$491,000 | — | 30 Sep 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.12%
|
225,000
|
$409,500 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.11%
|
207,657
|
$377,936 | — | 30 Sep 2025 | |
| Matthew K. Fust |
3/4/5
|
Director |
—
mixed-class rows
|
100,100
mixed-class rows
|
$342,395 | — | 28 May 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.1%
|
183,799
|
$334,514 | — | 30 Sep 2025 | |
| Addis & Hill, Inc |
13F
|
Company |
0.09%
|
163,386
|
$290,828 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.08%
|
157,806
|
$287,207 | — | 30 Sep 2025 | |
| Graham Capital Management, L.P. |
13F
|
Company |
0.08%
|
156,933
|
$285,618 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.08%
|
155,916
|
$283,767 | — | 30 Sep 2025 | |
| RBF Capital, LLC |
13F
|
Company |
0.07%
|
140,000
|
$254,800 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.07%
|
137,429
|
$250,121 | — | 30 Sep 2025 | |
| Alaa Halawa |
3/4/5
|
Director |
—
mixed-class rows
|
100,100
mixed-class rows
|
$240,798 | — | 28 May 2025 | |
| David Piacquad |
3/4/5
|
Director |
—
mixed-class rows
|
100,100
mixed-class rows
|
$240,798 | — | 28 May 2025 | |
| Maykin Ho |
3/4/5
|
Director |
—
mixed-class rows
|
100,100
mixed-class rows
|
$240,798 | — | 28 May 2025 | |
| UBS Group AG |
13F
|
Company |
0.07%
|
129,046
|
$234,864 | — | 30 Sep 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.06%
|
117,504
|
$213,857 | — | 30 Sep 2025 |
Institutional Holders of Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA) as of Q4 2025
As of 31 Dec 2025,
Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA) was held by
100 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
62,936,207 shares.
The largest 10 holders included
SOFTBANK GROUP CORP., Siren, L.L.C., VANGUARD GROUP INC, MIC Capital Management UK LLP, Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC, FMR LLC, WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST, ICONIQ Capital, LLC, and Lunate Capital Ltd.
This page lists
100
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
91
Q4 2025 holders
100
Holder diff
9
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.